Revolution Medicines, Inc.
RVMDWDrugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Daraxonrasib
Advanced Solid Tumors
gemcitabine
Pancreatic Cancer
Zoldonrasib
Pancreatic Cancer
RMC-6236
Non-small Cell Lung Cancer (NSCLC)
Elironrasib
Non-Small Cell Lung Cancer (NSCLC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Daraxonrasib | Phase 3 | Advanced Solid Tumors | - | - |
gemcitabine | Phase 3 | Pancreatic Cancer | - | - |
Zoldonrasib | Phase 3 | Pancreatic Cancer | - | - |
RMC-6236 | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | - | - |
Elironrasib | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Revolution Medicines, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Revolution Medicines, Inc.'s (RVMDW) pipeline across Phase 3, Phase 2. Its lead program is Daraxonrasib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Revolution Medicines, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Revolution Medicines, Inc. (RVMDW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RVMDW biotech catalysts?→
Add RVMDW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Revolution Medicines, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.